Dosage evidence

Tesamorelin Dosage: What the FDA Label Actually Says

The only peptide in this group with a current US label and a labeled daily dose — but the label is for HIV-associated lipodystrophy, not for general body composition or anti-aging use.

Where Tesamorelin stands with the FDA

Approved US drug product

The labeled doses

DoseRouteFrequencyApproved for
1.4 mg (0.35 mL of the reconstituted solution)
Current FDA label
Subcutaneous injectionOnce dailyEGRIFTA SV — reduction of excess abdominal fat in HIV-infected adults with lipodystrophy
1.28 mg
Current FDA label
Subcutaneous injection into the abdomenOnce dailyEGRIFTA WR — reduction of excess abdominal fat in HIV-infected adults with lipodystrophy

Read the “Approved for” column before anything else. A labeled dose belongs to the population it was studied in. It is not a general-purpose number, and it is not automatically the right dose for a different indication.

Convert your prescribed dose to syringe units

If a clinician has prescribed Tesamorelin for you, the number that matters next is how far to draw the syringe — and that depends on how much bacteriostatic water went into the vial, not on the peptide itself. Note the unit change: the doses above are written in milligrams, and the calculator takes micrograms. Multiply by 1,000 — a 1.4 mg dose is 1,400 mcg.

What this does — and what it does not

This converts a dose your prescriber has already given you into a volume and a number of units on a U-100 insulin syringe. It does not suggest a dose, and it does not tell you whether a peptide is appropriate for you. Most research peptides have no FDA-approved dosing, so there is no “standard” number for us to fill in. Doses here are in micrograms (mcg) — confusing mcg with mg is a 1,000-fold error and the single most common way people get this wrong.

Enter the dose your prescriber gave you, in micrograms, to see the volume and syringe units.

Your 5 mg vial in 2 mL of bacteriostatic water is .

Keep reading

References

  1. 1.Theratechnologies Inc. EGRIFTA WR (tesamorelin for injection) — US Prescribing Information, Dosage and Administration. FDA DailyMed. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
  2. 2.Theratechnologies Inc. EGRIFTA SV (tesamorelin for injection) — US Prescribing Information, Dosage and Administration. FDA DailyMed. 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224

This page reports what regulators and published sources say about Tesamorelin. It is not medical advice, not a recommendation to use Tesamorelin, and not a dosing instruction. Every source above was opened and read on the date recorded in our data; regulatory status changes, so check the primary source before relying on it.